Fredun Pharmaceuticals Ltd
Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]
- Market Cap ₹ 1,156 Cr.
- Current Price ₹ 2,097
- High / Low ₹ 2,200 / 666
- Stock P/E 35.4
- Book Value ₹ 293
- Dividend Yield 0.03 %
- ROCE %
- ROE 14.0 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 1.51% over last quarter.
Cons
- Stock is trading at 7.16 times its book value
- Promoter holding has decreased over last 3 years: -5.58%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | TTM | |
|---|---|---|
| 456 | 593 | |
| 401 | 511 | |
| Operating Profit | 55 | 83 |
| OPM % | 12% | 14% |
| 0 | 0 | |
| Interest | 22 | 33 |
| Depreciation | 5 | 7 |
| Profit before tax | 27 | 43 |
| Tax % | 28% | |
| 20 | 33 | |
| EPS in Rs | 41.81 | 66.55 |
| Dividend Payout % | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 64% |
| 5 Years: | 39% |
| 3 Years: | 32% |
| 1 Year: | 198% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Sep 2025 | |
|---|---|---|
| Equity Capital | 5 | 5 |
| Reserves | 137 | 153 |
| 167 | 171 | |
| 179 | 136 | |
| Total Liabilities | 487 | 464 |
| 53 | 66 | |
| CWIP | 0 | 0 |
| Investments | 2 | 2 |
| 433 | 397 | |
| Total Assets | 487 | 464 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| -29 | |
| -6 | |
| 39 | |
| Net Cash Flow | 4 |
| Free Cash Flow | -35 |
| CFO/OP | -53% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | 142 |
| Inventory Days | 265 |
| Days Payable | 160 |
| Cash Conversion Cycle | 247 |
| Working Capital Days | 76 |
| ROCE % |
Insights
In beta| Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daily Compression Capacity (Tablets) Million Units ・Standalone data |
|
|||||||||||
| Daily Granulation Capacity (Tablets) Kgs ・Standalone data |
||||||||||||
| Number of International Markets Present Countries ・Standalone data |
||||||||||||
| Number of Registered Products Globally Count ・Standalone data |
||||||||||||
| Products Under Registration Globally Count ・Standalone data |
||||||||||||
| Daily Topicals Capacity Tubes ・Standalone data |
||||||||||||
| Pet Care (Freossi) Product Portfolio SKUs ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
8h - Fredun Pharmaceuticals adds fifth Palghar facility; 40,000 sq. ft. operational by October 2026, with 50,000 sq. ft. planned.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
1d - Fredun Pharmaceuticals confirms it is not a SEBI large corporate for debt issuance.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 15 Apr
-
Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015.
13 Apr - Director Daulat Nariman Medhora received 40,000 shares on 9 April 2026 via warrant conversion.
-
Announcement under Regulation 30 (LODR)-Allotment
9 Apr - Board allotted 40,000 equity shares to promoter Mrs. Daulat Nariman Medhora upon warrant conversion for ₹3.75 crore.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2026TranscriptPPT
-
Nov 2025TranscriptPPTREC
-
Aug 2025TranscriptPPTREC
-
Jun 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Jun 2019TranscriptAI SummaryPPT
Business Overview:[1]
The company, a subsidiary of the Fredun Group, manufactures pharmaceutical and allopathic formulations including tablets, syrups, capsules, and ointments across therapeutic areas like anti-diabetics, anti-retrovirals, and anti-hypertensives. It has also expanded into dietary and herbal supplements, nutraceuticals, diagnostic kits, and animal healthcare products through group entities Fredun Healthcare Pvt. Ltd. and Fredna Enterprises.